Drug Profile
Research programme: MRSA vaccines - Abcombi Biosciences
Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Abcombi Biosciences
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 28 May 2022 No recent reports of development identified for research development in Methicillin-resistant-Staphylococcus-aureus-infections(Prevention) in USA (Parenteral)
- 10 Apr 2018 Early research in Methicillin-resistant Staphylococcus aureus infections (Prevention) in USA (Parenteral) (Abcombi Biosciences pipeline, April 2018)